Learn More
PURPOSE To evaluate the quality of life (QOL) of breast cancer patients who survived 2 to 5 years following initiation of adjuvant cytotoxic and/or hormonal therapy and to characterize relationships between QOL and patient physical symptoms, sexual function, and preferences regarding adjuvant treatment. PATIENTS AND METHODS Eighty-six patients who had(More)
The aim of this study was to design and develop controlled release Imatinib mesylate (IM) oral dosage form by fabricating gastroretentive mucoadhessive tablet which can retain the drug in the stomach for prolonged duration and to achieve therapeutic levels over an extended period of time for the treatment of myelogenous leukemia (CML) and gastro intestinal(More)
  • 1